Compare BFRI & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRI | NAII |
|---|---|---|
| Founded | 1997 | 1980 |
| Country | United States | United States |
| Employees | 94 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 15.8M |
| IPO Year | N/A | 1995 |
| Metric | BFRI | NAII |
|---|---|---|
| Price | $1.19 | $2.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | ★ 393.6K | 10.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $132,437,000.00 |
| Revenue This Year | $14.36 | N/A |
| Revenue Next Year | $16.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.60 |
| 52 Week Low | $0.57 | $2.09 |
| 52 Week High | $1.27 | $4.96 |
| Indicator | BFRI | NAII |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 46.86 |
| Support Level | $0.71 | $2.09 |
| Resistance Level | N/A | $2.83 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 74.55 | 44.09 |
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.